EMA Greenlights Combined HLA Enrollment in FLAMINGO-01, Doubling Potential Market
GLSI has more than doubled off its 52-week low of $7.78 on light trading volume (0.3× avg).
Summary
The EMA has approved combining both HLA-A*02 and non-HLA-A*02 patients in the same randomized arms of the Phase III FLAMINGO-01 trial, matching the FDA's earlier decision. All 170-180 US and European sites now operate under one protocol, which more than doubles the enrollment rate for the pivotal arm. Preliminary open-label data from the fully enrolled 250-patient non-HLA-A*02 arm shows a 70-80% reduction in recurrence rate after the primary immunization series, trending similarly to the Phase IIb results. This opens a pathway to pursue approval for both HLA types, potentially doubling the addressable market for GP2. The update follows the July 9 European approval for commercially manufactured GP2 and adds significant clinical validation. With a going concern warning and rising cash burn, positive trial progress is critical for the company's outlook.
At the time of this announcement, GLSI was trading at $20.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $286.8M. The 52-week trading range was $7.78 to $34.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.